Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 9.1% as of 11:31 a.m. ET on Tuesday after rising as much as 13% earlier in the day. The nice gain came after the company provided its second-quarter update on Monday following the market close.

CRISPR Therapeutics reported second-quarter revenue of $70 million. It posted a net loss of $77.7 million, or $0.98 per share. Both results topped consensus estimates.

Two analysts also issued positive updates after the results were announced. Needham reiterated coverage of the stock with a buy recommendation. Credit Suisse's Richard Law reiterated a neutral rating for the gene-editing stock but increased his price target from $62 to $63. 

Continue reading

Source Fool.com